Kymera Therapeutics, Inc. Common Stock vs. Repligen Corp
Repligen Corp (RGEN) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| KYMR | RGEN | |
|---|---|---|
| Market Cap | $9.48 billion | $9.35 billion |
| Revenue (TTM) | $105.00 million | $785.10 million |
| Net Income (TTM) | $-299,601,000 | $41.54 million |
RGEN leads on 2 of 3 size & scale factors.
Valuation
| KYMR | RGEN | |
|---|---|---|
| P/E Ratio | — | 228.53 |
| Price / Book | 6.28 | 4.43 |
| Price / Sales | 90.30 | 11.91 |
RGEN leads on 2 of 2 valuation factors.
Profitability
| KYMR | RGEN | |
|---|---|---|
| Net Margin | -285.34% | 5.29% |
| Return on Equity | -19.85% | 1.97% |
RGEN leads on 2 of 2 profitability factors.
Risk & Sentiment
| KYMR | RGEN | |
|---|---|---|
| Short Interest | 0.24% | 7.13% |
KYMR leads on 1 of 1 risk & sentiment factors.
Dig deeper: KYMR overview, KYMR financials, RGEN overview, RGEN financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.